The University of Chicago Header Logo

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy.

Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer Med. 2018 Jul; 7(7):2943-2950.

View in: PubMed